Newark, New Jersey Clinical Trials

Swiss Pediatric Inflammatory Brain Disease Registry (Swiss-Ped-IBrainD)  

The Swiss-Ped-IBrainD is a national patient registry that collects information on diagnosis, symptoms, treatment, and follow-up of pediatric patients with an inflammatory brain disease in Switzerland. It was first implemented in 2020 in the pediatric clinic of the university hospital in Bern. Further centers all over Switzerland were opened for …

Kantonsspital Aarau

(online study)

Salivary Immune/Stress Biomarkers Among Children

Background: The use of easily accessible biomarkers for assessing young patients' health is important. This study's aim is a measuring stress/immune biomarkers in saliva of healthy school-age children and compare subgroups according to age, sex, stress perception in dental pain related to symptomatic irreversible pulpitis (SIP) and symptomatic apical periodontitis …

Poznan University of Medical Sciences

(online study) Contact site

PET MRI as a Staging Tool for Head and Neck Cancer

To explore the use of PET/MRI in the staging and pretreatment evaluation of patients with head and neck cancer and to compare this modality to standard PET/CT imaging.

Hoag Memorial Hospital Presbyterian

(online study) Contact site

A Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer

This study is being done to see if tucatinib with ado-trastuzumab emtansine (T-DM1) works better than T-DM1 alone to help patients who have a specific type of breast cancer called HER2 positive breast carcinoma. The breast cancer in this study is either metastatic (spread into other parts of the body) …

Saint Barnabas Medical Center Cancer Center

 (6.5 away) Contact site

Treatment With Romosozumab Versus Denosumab to Improve Bone Mineral Density and Architecture in Subacute SCI  

The objective of the proposed work is to determine whether administration for 12 months of romosozumab followed by 12 months of denosumab will maintain bone mass at the knee in subjects with subacute SCI compared to 24 months of denosumab administration alone.

Kessler Institute for Rehabilitation

 (4.4 away)

formal test 1

This is formal test 1 trial

Site 1

 (6.0 away) Contact site

TS1

Site 1

 (6.0 away) Contact site

TS5

Site 1

 (6.0 away) Contact site

Test SSO Now 2 Update  

Please see section 3 of the full protocol Please see section 3 of the full protocol Please see section 3 of the full protocol

Hospital of the University of Pennsylvania

(online study)

22 Sep 2023 -11

Please see section 3 of the full protocol Please see section 3 of the full protocol Please see section 3 of the full protocol1

SSO Site 3

(online study) Contact site